Market Performance - Major market indices opened with mixed results, with the Shanghai Composite Index rising by 0.09% to 4086.76 points, while the Shenzhen Component Index fell by 0.30% to 13917.78 points, and the ChiNext Index decreased by 0.69% to 3279.38 points [1] Individual Stock Performance - A total of 2051 stocks rose at the opening, with 25 stocks hitting the daily limit up, including Fenglong Co. with 11 consecutive limit ups, *ST Dongyi with 13 limit ups in 10 days, and Luxin Investment with 11 limit ups in 9 days [1] - Conversely, 2493 stocks declined at the opening, with 2 stocks hitting the daily limit down, namely ST Derun and *ST Chuntian [1] Price Continuity Statistics - Among the stocks that hit the limit up yesterday, 21 stocks continued to hit the limit up today, including Zhizhi New Materials and Hangxiao Steel Structure [1] - Stocks that opened lower today included Puni Testing, Bibet, and Aipeng Medical, with declines of 8.20%, 7.41%, and 6.03% respectively [1] - Among the stocks that hit the limit down yesterday, ST Derun and *ST Chuntian continued to hit the limit down today [1]

Market Sentiment - The current market sentiment score is 82, indicating an "overheated" market condition, which suggests a high level of investor optimism [5][7][21]. Hot Themes Tracking - **Robotics Theme**: The establishment of a national standard organization for humanoid robots and embodied intelligence marks a transition from "technical exploration" to "industrial collaboration" and "scale deployment," which is expected to accelerate technology implementation and ecosystem formation. Related stocks include Sanhua Intelligent Control (002050) and Wolong Electric Drive (600580) [5]. - **Banking Theme**: Bank stocks exhibit high dividend characteristics, with the CSI Bank Index yielding 6.02%, significantly higher than the 10-year government bond yield. In a slowing economy with increased market volatility, bank stocks become important investment targets for long-term funds such as insurance and social security. Related stocks include Agricultural Bank of China (601288) and Ningbo Bank (002142) [5]. - **Brain-Computer Interface Theme**: Neuralink plans to begin large-scale production of brain-computer interface devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process. The global brain-computer interface market is projected to reach $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034. Related stocks include Aipeng Medical (300753) and Maipu Medical (301033) [5]. Capital Flow Analysis - The top ten stocks with the highest net inflow include Aerospace Science and Technology (000901.SZ) with a net inflow of 909.93 million, and Hailanxin (300065.SZ) with 887.38 million [8]. - The top ten stocks with the highest net outflow include Zhongji Xuchuang (300308.SZ) with a net outflow of 322.72 million, and Lixun Precision (002475.SZ) with 219.50 million [13]. - The top ten industries with the highest net inflow include Defense and Military (SW) and Computer (SW), while the industries with the highest net outflow include Electronics (SW) and Non-bank Financials (SW) [16][22].

Group 1 - The core focus of the news is the surge in stock prices of companies involved in brain-computer interface (BCI) technology, reminiscent of the AI boom following AlphaGo's victory over Lee Sedol in 2016, with a notable increase in the sector's stock prices exceeding 12% on the first trading day of 2026 [1] - Companies like Sanbo Neuroscience and Xiangyu Medical have experienced consecutive trading halts, with Xiangyu Medical and Weisi Medical achieving two 20% trading halts in four trading days, indicating strong market interest [1] - The market's enthusiasm is driven by the perceived potential of the BCI sector, with Morgan Stanley predicting that the U.S. market for BCI implant devices could reach $80 billion by 2035 [1] Group 2 - Despite the excitement, experts caution that medical-grade applications of BCI are expected to take 3 to 5 years for approval, while consumer-grade products face challenges such as bulkiness, low user engagement, and high costs [2] - Historical precedents raise concerns about the sustainability of the current hype, with past instances like the metaverse index and AI stocks experiencing significant volatility [2] - Investment in the BCI sector has seen 16 financing events totaling 983 million yuan in 2025, but no products have been commercially launched yet, indicating that many startups are still in the concept validation stage [2] Group 3 - Sanbo Neuroscience clarified that it does not engage in the research, production, or sales of BCI products, and the revenue from neuro-regulation technology is minimal, having little impact on overall performance [3] - Xiangyu Medical acknowledged its investment in BCI technology but noted that related products have not achieved significant sales volume as of the end of 2025 [3] - Some companies, like Yahui Long, faced regulatory warnings for inaccurate disclosures related to BCI partnerships, highlighting the risks of speculative trading in this sector [3]

Market Overview - The A-share market experienced significant differentiation after a strong rally, with the Shanghai Composite Index slightly retreating by 0.07% to 4082.98 points, while the Sci-Tech Innovation Index rose by 1.14% to 1766.57 points, driven by sectors like brain-computer interfaces and controllable nuclear fusion [2] Brain-Computer Interface Sector - The brain-computer interface sector saw strong performance, with stocks like Aipeng Medical hitting a 20% limit-up, and companies such as Nanjing Panda and Prit reported consecutive gains [3] - Nanjing Panda clarified that it currently has no mature products related to brain-computer interfaces and that the concept will not materially impact its operations [3] - Prit disclosed that its LCP film products are suitable for use as flexible electrode materials in brain-computer interfaces, and it is the only domestic company to achieve a significant technological breakthrough in this area [3] Controllable Nuclear Fusion Sector - The controllable nuclear fusion concept experienced a surge, with over ten stocks, including China Nuclear Engineering and Snowman Group, hitting the limit-up [4] - The sector has seen a cumulative increase of nearly 10% since the beginning of 2026, indicating strong market interest [4] Technological Breakthroughs in Nuclear Fusion - Recent breakthroughs in controllable nuclear fusion technology were reported by the Hefei Institute of Physical Science, which confirmed significant experimental results related to the "artificial sun" superconducting tokamak [5] - The International Energy Agency predicts that the global nuclear fusion market could approach 3.5 trillion yuan by 2030, highlighting the sector's potential [5] - The past five years have shown explosive growth in the global fusion industry, with total investments rising from $1.9 billion in 2021 to $9.7 billion, and an additional $2.6 billion expected in 2024 [5] Investment Outlook - UBS's China president stated that Chinese assets are not in a "heated" state, with expected earnings growth of 14% for the MSCI China Index in 2026, driven by sectors like internet platforms and high-end manufacturing [6] - UBS's internal data indicates that foreign investment in Chinese assets is expected to rebound significantly, although there remains considerable room for growth compared to historical averages [6] - The valuation advantages and structural growth potential of Chinese assets make them an attractive option for global investors seeking to hedge against single-market risks [6]

南财智讯1月8日电，爱朋医疗公告，北京章泓私募基金管理有限公司-章泓精选1号私募证券投资基金因 自身资金需求，于2025年12月5日至2026年1月7日通过集中竞价方式减持公司股份755,700股，减持均价 为28.33元/股。本次权益变动后，该基金持有公司股份6,302,300股，占公司总股本比例由5.60%下降至 4.99%，持股比例已降至5%以下。本次权益变动不会导致公司实际控制人发生变化，且所持股份不存在 质押、冻结等权利限制情形。 ...

江苏爱朋医疗科技股份有限公司 简式权益变动报告书 上市公司名称：江苏爱朋医疗科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：爱朋医疗 股票代码：300753 信息披露义务人：北京章泓私募基金管理有限公司-章泓精选 1 号私募证券投资基金 基金管理人：北京章泓私募基金管理有限公司 管理人注册地址：北京市房山区北京基金小镇大厦 C 座 441 股份变动性质：股份减少，持股比例降至 5%以下 签署日期：2026 年 1 月 8 日 1 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收购管理办法》"）、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》（以下简称 "《第15号准则》"）及相关的法律法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反信息 披露义务人章程或者内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购管理办法》《第15号准则》的规定，本报告书已全面披 露了信息披露义务人在江苏爱朋医疗科技股份有限公司拥有权益的股 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2026-002 特别提示： 1、本次权益变动属于股东减持公司股份，不触及要约收购，不会导致公司控股股 东及实际控制人发生变化。 2、本次权益变动后，北京章泓私募基金管理有限公司-章泓精选 1 号私募证券投资 基金持有公司股份 6,302,300 股，占公司总股本的 4.9999%，不再是公司持股 5%以上的 股东。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于 2025 年 11 月 12 日在巨 潮资讯网（http://www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股份的预披 露公告》（公告编号：2025-052），持有本公司 7,058,000 股（占公司总股本的 5.60%）的持股 5%以上股东北京章泓私募基金管理有限公司-章泓精选 1 号私募证券投 资基金（以下简称"章泓基金"），计划自上述公告披露之日起十五个交易日后的三 个月内以集中竞价交易方式减持所持有的本公司股份不超过 1,260,480 股（占公司总股 本的 1%）；以大宗交易方式减持所持有的本公司股份不超过 1,260,480 股（占公司总 股本的 1%） ...

Core Insights - The medical device sector experienced a rise of 1.14% on January 8, with Kangtong Medical leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] Medical Device Sector Performance - Kangtong Medical (301515) closed at 25.48, up 20.02% with a trading volume of 123,300 shares and a transaction value of 291 million [1] - Yuanpeng Medical (300753) closed at 42.62, up 19.99% with a trading volume of 471,600 shares and a transaction value of 1.884 billion [1] - Kefu Medical (301087) closed at 54.00, up 13.52% with a trading volume of 174,300 shares and a transaction value of 92.86 million [1] - Shuoshi Biology (688399) closed at 77.21, up 13.31% with a trading volume of 73,500 shares and a transaction value of 550 million [1] - Anbiping (688393) closed at 27.60, up 6.73% with a trading volume of 69,500 shares and a transaction value of 189 million [1] Capital Flow Analysis - The medical device sector saw a net inflow of 533 million from institutional investors, while retail investors experienced a net outflow of 450 million [2][3] - Yuanpeng Medical had a net inflow of 225 million from institutional investors, but a net outflow of 103 million from retail investors [3] - Lepu Medical (300003) had a net inflow of 181 million from institutional investors, with a net outflow of 67.8 million from retail investors [3]

Group 1 - The brain-computer interface concept has seen a rise of 3.27%, ranking 9th among concept sectors, with 56 stocks increasing in value [1] - Notable stocks that reached the daily limit include Kangtong Medical, Aipeng Medical, and Puni Testing, all achieving a 20% increase, while Nanjing Panda, Pulit, and Innovation Medical also hit the limit [1] - Leading gainers in the sector include Kefu Medical, Yinkang Life, and Danghong Technology, with increases of 13.52%, 7.39%, and 6.67% respectively [1] Group 2 - The brain-computer interface sector attracted a net inflow of 1.115 billion yuan, with 41 stocks receiving net inflows, and 9 stocks exceeding 100 million yuan in net inflow [2] - The top stock for net inflow is Yanshan Technology, with a net inflow of 974 million yuan, followed by Seli Medical, Hainan Haiyao, and Aipeng Medical with net inflows of 314 million yuan, 272 million yuan, and 237 million yuan respectively [2] Group 3 - In terms of net inflow ratio, Innovation Medical, Seli Medical, and Beilu Pharmaceutical lead with ratios of 51.56%, 17.45%, and 16.93% respectively [3] - The brain-computer interface sector's top stocks by net inflow include Yanshan Technology with a 9.96% increase and a turnover rate of 34%, and Seli Medical with a 9.98% increase and a turnover rate of 33.31% [3][4]

Core Viewpoint - The artificial intelligence sector continues to show strong performance, with multiple stocks experiencing significant gains, reflecting positive market sentiment towards AI-related policies and developments [1][6]. Group 1: Stock Performance - On January 8, 21 stocks in the AI sector reached their daily limit up, including Aipeng Medical, Zhite New Materials, Meike Home, and others [1]. - Notably, Zhite New Materials, Meike Home, and others achieved a "4 consecutive limit up" status, while Far East Holdings reached a "3 consecutive limit up" [2]. - The top performers included Zhongcheng Technology (+22.67%), Aipeng Medical (+19.99%), and Zhite New Materials (+19.98%) [3]. Group 2: Policy Developments - On January 7, the Ministry of Industry and Information Technology and other departments released the "Implementation Opinions on the 'Artificial Intelligence + Manufacturing' Special Action," aiming to accelerate the integration of AI technology in manufacturing [1][4]. - The policy sets ambitious goals for 2027, including the development of 3 to 5 general large models for deep application in manufacturing and the creation of 100 high-quality industrial data sets [4][5]. - The initiative emphasizes the importance of innovation investment and the cultivation of globally influential enterprises in the AI sector [5]. Group 3: Market Dynamics - The listing of Zhipu AI on the Hong Kong Stock Exchange on January 8, with an opening price of HKD 120 per share and a market capitalization exceeding HKD 52.8 billion, is expected to inject new capital into the AI sector [6]. - The overall AI sector showed a strong upward trend on January 8, with significant capital flowing into application areas focused on industrial machinery, indicating a positive market response to policy directions [6]. - However, there is a noted structural differentiation within the sector, with some previously high-performing stocks experiencing profit-taking, suggesting potential short-term volatility risks [6][7]. Group 4: Industry Outlook - Dongxing Securities reports that the AI industry is currently in a phase of resonance among policy, technology, and demand, supported by top-down policy empowerment and potential funding [7]. - The industry is expected to maintain upward momentum, with a strong position in technology investment that is unlikely to be disrupted [7].